- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00388115
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
A Pilot Study of Radiofrequency Ablation of Early Invasive and In Situ Breast Cancer
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving radiofrequency ablation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This clinical trial is studying how well radiofrequency ablation followed by surgery works in treating patients with early invasive breast cancer or ductal carcinoma in situ.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Determine the effectiveness of radiofrequency ablation (RFA), in terms of amount of tumor coagulated and viable cell count, in patients with early invasive breast cancer or low- or intermediate-grade ductal carcinoma in situ.
Secondary
- Determine the size, configuration, and pathological features of human breast tumors after treatment with RFA.
- Determine whether RFA energy applied to breast cancer will result in cancer cell death.
- Determine whether tumor-free margins are achieved by RFA in these patients.
- Determine the rate of acute toxicities to skin after surgery in patients treated with this regimen.
OUTLINE: This is a pilot study.
- Pre-radiofrequency ablation (RFA) procedures: Patients undergo staging by MRI assessment to determine the size of their tumor. Patients with nonpalpable lesions must undergo placement of a metallic clip in the center of their tumor and a hook wire to guide surgical excision by intraoperative ultrasound imaging. Patients with invasive breast cancer undergo axillary lymph node dissection or sentinel lymph node biopsy (SLNB) for axillary lymph node staging. Patients with ductal carcinoma in situ proceed directly to RFA/resection since they do not require axillary staging.
- RFA: Patients undergo RFA comprising insertion of a multiple-needle electrode into the breast tumor under direct guidance of ultrasonography and the metallic clip placed preoperatively in the lesion.
- Surgical resection of RFA area: After RFA is completed, the electrode is removed and patients undergo wide local excision of the residual tumor or mastectomy.
After completion of study therapy, patients are followed periodically for up to 4 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Females of ages ≥18 years.
- Core biopsy proven invasive breast cancer OR
- Core biopsy proven low or intermediate grade DCIS.
- Tumor less than or equal to 2.0 cm in diameter.
- No prior surgical treatment for breast cancer within 30 days.
- Life expectancy of > 10 years, not including the diagnosis of cancer.
- ECOG performance status of 0-2.
- Informed consent given.
- Multifocal invasive breast cancer patients are eligible. All tumors that are palpable or visualized by USS can be treated.
Exclusion Criteria:
- Male subjects.
- Ages < 18 years.
- Breast tumor > 2.0 cm in diameter.
- Evidence of distant metastatic disease.
- Evidence of diffuse calcification suggestive of extensive or multifocal DCIS.
- High grade DCIS or presence of comedo-necrosis because these lesions can be associated with invasive breast cancer, which would go undetected if the lesion is entirely destroyed by the RF ablation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: RFA prior to surgery
|
Standard of care lumpectomy or mastectomy following RFA
Standard of care lumpectomy or mastectomy following RFA
A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current.
Initial power of the RF generator will start at 5-10 watts.
The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Number and proportion of patients with viable cancer cells remaining in the resected specimen as measured by enzyme cell viability analysis and amount of tumor coagulated at post-treatment biopsy
Zeitfenster: At completion of study
|
At completion of study
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Number and proportion of patients with uncoagulated tumor remnant at post-treatment biopsy
Zeitfenster: At completion of study
|
At completion of study
|
Number and proportion of patients with and without tumor in the margin
Zeitfenster: At completion of study
|
At completion of study
|
Rate of acute skin toxicity
Zeitfenster: At completion of study
|
At completion of study
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Vijay Khatri, MD, University of California, Davis
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CDR0000505536
- P30CA093373 (US NIH Stipendium/Vertrag)
- UCD-123 (Andere Kennung: University of California, Davis - Cancer Center)
- UCD-200210277-6 (Andere Kennung: University of California, Davis - IRB)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur conventional surgery
-
Columbia UniversityAbbott NutritionRekrutierungHerzfehler | Darm-Mikrobiom | ErnährungsmangelVereinigte Staaten
-
Royal Surrey County Hospital NHS Foundation TrustUnbekanntEierstockkrebs | Eileiterkrebs | Bauchfellkrebs | Eierstock-Neoplasma | Eierstock-Neoplasma EpithelialVereinigtes Königreich
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteRekrutierungArthrose, HüfteVereinigtes Königreich
-
NYU Langone HealthNoch keine RekrutierungEntzündliche DarmerkrankungenVereinigte Staaten
-
University of Colorado, DenverRekrutierungVerbesserte Erholung nach der Operation | Gynäkologische ErkrankungVereinigte Staaten
-
Mayo ClinicBeendetGastroösophagealer Reflux | Hernie, Hiatal | Umfragen und Fragebögen | FundoplikatioVereinigte Staaten
-
NYU Langone Health7D Surgical Inc.ZurückgezogenSkoliose | Spinale Stenose | Spondylolisthese
-
Dr. Faruk SemizAnmeldung auf Einladung
-
Radboud University Medical CenterAktiv, nicht rekrutierendProstatakrebs | LymphknotenmetastasenNiederlande
-
University of TriesteAbgeschlossen